Synedgen Receives $1.96 million from the NIH to Accelerate the Development of a Promising New Treatment for Oral Mucositis

Share Article

Treatment is being developed to reduce oral infection and pain associated with cancer treatments

We are pleased to be working with the NIH on this important need and are dedicated to developing a safe and effective product that reduces the pain and suffering associated with cancer treatment

Biotech firm Synedgen announces the award of a competitive Phase II SBIR grant by the National Institutes of Health (NIH) to accelerate the development of Synedgen’s proprietary oral disease treatments. Under this 2-year $1.96 M effort, starting on April 1, Synedgen will accelerate the development of RegenasynTM, a topical treatment for oral mucositis that both prevents infection and improves healing.

Oral mucositis is a common debilitating side effect of chemotherapy, radiotherapy and immune compromise, conditions that reduce the ability of cells in the oral cavity to heal and grow. Swelling and ulceration of oral tissues occurs and increases the chances of infection. Patients with severe oral mucositis have painful oral lesions that can significantly reduce their ability to eat and drink.

“Severe oral mucositis is the leading reason cancer patients stop or delay treatment. While there are very limited therapies to reduce the symptoms of mucositis in some chemotherapy and immunosuppressed patients, no current treatment provides successful improvement in radiation-induced mucositis. This award will accelerate Synedgen’s development of our product to prevent and treat these painful lesions, and support our efforts to prepare for human clinical trials as soon as possible”, stated Synedgen President Shenda Baker.

Laboratory and animal research with Synedgen’s lead products have demonstrated remarkable anti-inflammatory and tissue regenerative properties in injured and damaged tissues. “We are pleased to be working with the NIH on this important need and are dedicated to developing a safe and effective product that reduces the pain and suffering associated with cancer treatment”, remarked Synedgen CEO William Wiesmann.

The project is supported by Award Number 2R44DE019740-02 from the National Institute Of Dental & Craniofacial Research. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institute Of Dental & Craniofacial Research or the National Institutes of Health.

For Immediate Release

Media contact: Nicole Draghic
Tel: 301-428-9818

###

Share article on social media or email:

View article via:

Pdf Print

Contact Author

Nicole Draghic

301-428-9818 ext. 250
Email >
Visit website